The nitric oxide asthma testing market will exhibit consistent expansion between 2025 and 2035 because the asthma prevalence keeps rising and physicians focus on non-invasive testing devices and medical professionals better understand personalized respiratory care.
The assessment of airway inflammation relies heavily on fractional exhaled nitric oxide (FeNO) testing as part of the airway inflammation assessment tool for asthma management optimization. The market value will start at USD 2,751.4 million in 2025 and project to grow up to USD 4,439.3 million by 2035 while sustaining a compound annual growth rate (CAGR) of 4.9% during this period.
The market expands because asthma diagnoses in adult and child populations continue to increase and research verifies FeNO analysis value and doctors adopt NO analyzers as part of standard pulmonary practice. The market adoption grows because of emerging digital healthcare technologies and increasing popularity of home monitoring devices.
Equipment expenses remain high as certain areas do not fully reimburse for these products while primary care practitioners do not conduct sufficient procedures. The market sees manufacturers develop portable and cost-effective analyzers while increasing their healthcare training initiatives.
Key Market Metrics
| Metric | Value |
|---|---|
| Industry Size (2025E) | USD 2,751.4 million |
| Industry Value (2035F) | USD 4,439.3 million |
| CAGR (2025 to 2035) | 4.9% |
This market solves asthma assessments through nitric oxide testing and it distinguishes itself through various device types which are widely adopted by hospitals and clinics and homecare settings. The market contains portable analysis instruments and desktop analysis devices among its primary segments.
Portable analyzers dominate the market because users benefit from their compatibility with point-of-care testing protocols as well as their potential use during telehealth sessions. Specialty respiratory clinics together with hospitals demonstrate the highest level of Nitric Oxide Asthma Testing Market adoption because they perform advanced diagnostics on high patient numbers.
Patient care services in both primary care centers and at home are experiencing expanding adoption because they focus on enhanced asthma management over the long-term and patient treatment adherence. More extensive awareness of FeNO testing along with its integration between spirometry and digital tracking systems improves patient outcomes by boosting diagnostic precision and patient interaction.
Explore FMI!
Book a free demo
North America accounts for a leading share of the nitric oxide asthma testing market for a number of reasons, including high level of asthma screening programs, comprehensive insurance coverage, and early adoption of novel diagnostic tools. Clinical guidelines supporting FeNO use are led by United States and Canada.
Increased use in pediatric asthma care and regulatory approval of NO analyzers and public health initiatives aiming at asthma management positions the Europe market as a leading one in the global exhaled NO analyser market. Others like Germany, the UK, and Netherlands back its reimbursement and training of physicians.
The nitric oxide asthma testing market is segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa; North America accounts for the majority of the nitric oxide asthma testing market share, driven by increasing asthma prevalence in the USA, technological advancement in the healthcare sector, and early detection of diseases. Investments in respiratory care programs by China, India, Japan, and South Korea bolster regional market growth.
High Equipment Cost and Limited Adoption in Primary Care
There are some challenges in the nitric oxide asthma testing market which include the high cost of testing devices as well as limited accessibility of testing devices outside specialty clinics and/or hospitals. Fractional exhaled nitric oxide (FeNO) testing is a non-invasive, accurate measure of airway inflammation and is especially valuable in patients with eosinophilic asthma.
But the high cost of analyzers, maintenance needs and the necessity for trained personnel limit broader use in primary care and rural environments. Moreover, general practitioners have little knowledge about FeNO testing and continue to use spirometry and symptom-based assessment, which neither assesses nor indicates underlying inflammation. As a result, diagnostic underutilization and variable insurance coverage continue to stymie market penetration.
Precision Medicine, Early Diagnosis, and Treatment Monitoring
The market has a high potential due to increasing demand for personalized asthma management and early inflammatory biomarker detection. As we know that FeNO testing gives crude on-line evaluation of airway inflammation, it allows clinician to differentiate between allergic (eosinophilic) and non-eosinophilic asthma phenotypes and offers the opportunity to target the intervention (corticosteroids) thus limiting unnecessary drugs.
The move toward more biomarker-directed therapy of asthma has led to the development of a biomarker-based profile that predicts exacerbations, adherence to therapy, and useful steps in guiding step-down therapy (i.e., dose reduction) after an exacerbation is resolved, leading to increasing interest in the role of FeNO testing.
FeNO is increasingly recognized around the world as an important measure for personal health improvement, and the growing prevalence of asthma and FeNO official guidance as part of routine diagnostics create opportunities for wider adoption, especially as portable and low-cost FeNO analyzers become available on the market.
2020 to 2024, FeNO testing is gaining traction in pulmonology and allergy specialty clinics as there will be more awareness of airway inflammation control and corticosteroid optimization. FeNO was encouraged as a useful adjunct to spirometry and symptom questionnaires by clinical trials and respiratory society guidelines.
Yet reimbursement hurdles, the high cost of the devices, and limited access outside specialist settings stymied broader adoption. However, the market remained hindered by the presence of potential barriers, such as low pediatric adoption and high silos across FeNO thresholds in the patient population.
During the period from 2025 to 2035, the market will transition toward integrated asthma management ecosystems where FeNO testing is coupled with digital inhaler tracking, mobile apps and AI based symptom tracking.
Miniaturised, usable FeNO devices come to market for point-of-care and home use (remote monitoring and personalised treatments). Advances in biosensor design, cloud-based data analytics, and wearable respiratory technology will cement FeNO’s role in the management of asthma control, adherence, and prediction of early exacerbations, establishing this specialty diagnostic as a mainstream respiratory health tool.
Market Shifts: A Comparative Analysis (2020 to 2024 vs. 2025 to 2035)
| Market Shift | 2020 to 2024 |
|---|---|
| Regulatory Landscape | FeNO testing recognized in clinical guidelines, but reimbursement varied. |
| Technological Advancements | Use of clinic-based analyzers with calibration needs and fixed settings. |
| Sustainability Trends | Minimal environmental focus due to limited device volume and clinical use. |
| Market Competition | Dominated by a few specialty respiratory diagnostic manufacturers. |
| Industry Adoption | Common in asthma clinics and tertiary care centers. |
| Consumer Preferences | Focused on accuracy and specialist interpretation. |
| Market Growth Drivers | Growth driven by clinical demand for inflammation assessment. |
| Market Shift | 2025 to 2035 |
|---|---|
| Regulatory Landscape | Adoption of unified insurance frameworks, pediatric inclusion, and regulatory incentives for home-use devices. |
| Technological Advancements | Rise of portable, AI-supported, app-integrated FeNO monitors for home and primary care. |
| Sustainability Trends | Emergence of eco-designed devices, low-waste cartridges, and digital health integration to minimize clinical burden. |
| Market Competition | Entry of digital health startups, device miniaturization firms, and mobile health platform providers. |
| Industry Adoption | Expanded to primary care, pediatric practices, telehealth, and community health programs. |
| Consumer Preferences | Preference for portable, user-friendly tools with remote tracking and real-time alerts. |
| Market Growth Drivers | Expansion fuelled by digital health integration, home care models, and biomarker-based asthma management. |
The United States nitric oxide asthma testing analysis market is growing at a moderate pace, credited with the increasing cases of asthma, high penetration of non-invasive diagnostics, and awareness about FeNO testing in clinical practice. FeNO analyzers have also been employed by pulmonologists and allergists to monitor airway inflammation and assist in guiding corticosteroid therapy, primarily in children and difficult-to-treat asthma cases.
The advances in the USA healthcare system in personalized medicine, digital spirometry, and reimbursement for FeNO testing will accelerate the integration of nitric oxide analysis into standard-of-care pathways in asthma. The market is also bolstered by school-based screening programs and urban respiratory health programmes.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 5.2% |
The UK nitric oxide asthma testing market is expanding at a solid pace, by virtue of NHS facilitated studies to reduce hospital cases attached with asthma and enhance disease management. FeNO testing is increasingly used in primary care settings as a reliable means of detecting eosinophilic inflammation and optimizing inhaled corticosteroid therapy.
Given the number of people with asthma, and children in particular, the point-of-care FeNO monitors are being incorporated into GP clinics and community providers of healthcare. Evidence-based asthma pathways in the UK are a significant driving force for this technology uptake.
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 4.7% |
The European nitric oxide asthma testing market is projected to grow at a remarkable rate owing to increasing prevalence of respiratory diseases, government backing for non-invasive diagnostic techniques and expanding availability of primary care testing tools. Germany, Sweden and the Netherlands are among the countries where FeNO testing is being incorporated into asthma management guidelines.
The changing reimbursement landscape and the drive to reduce the over-prescription of steroids are supporting FeNO device adoption. Assessment throughout the EU is encouraging development in portable nitric oxide devices outside the hospital.
| Region | CAGR (2025 to 2035) |
|---|---|
| European Union | 4.9% |
The Japanese market for nitric oxide asthma testing is growing steadily, driven by a robust respiratory care infrastructure and increasing focus on managing asthma for pediatric patients. FeNO tests help clinicians in Japan determine allergic rather than non-allergic asthma to use steroid responders.
As the country emphasizes high-precision medical diagnostics, the adoption of compact, hospital-grade FeNO analyzers is supported. Other clinical establishments including academic hospitals and respiratory clinics are also participating in more clinical verification of FeNO in asthma phenotyping, thereby enhancing the market development.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 4.6% |
Growing urban asthma incidence, government-supported respiratory health initiatives, and advanced diagnostic facilities Stimulate the steady growth of the South Korean nitric oxide asthma testing market The increase in allergic asthma, a risk factor for FeNO for children and young adults, is driving the widespread use of FeNO analyzers that are used in hospital and school screening programs.
With its integration of digital health tools and real-time diagnostic platforms, South Korea is a promising landscape for portable and app-connected FeNO devices. As such, chronically inclining to early asthma detection public health education with the market, it is all set to hold high growth potential.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 5.1% |
Nitric oxide asthma testing, though, is expected to meet this demand by providing a clinical, non-invasive tool for monitoring airway inflammation in patients, and tailoring personalized treatment for them. Measuring the levels of exhaled nitric oxide (FeNO) has developed as an accurate non-invasive approach to inform asthma diagnosis, assess inflammation, and determine steroid-induced responsiveness.
Currently, portable nitric oxide testing monitors are the most predominant technology because of their portability and ease of use. On the other hand, hospitals and clinics are the major end user segment for integrated diagnostics market in both emergency and outpatient settings. Collectively, these segments span market advancement with access to point-of-care asthma evaluation abilities in real time.
With rising asthma prevalence internationally, clinicians seek rapid, cost-efficient testing devices that can be adopted in standard clinical workflows. Handheld monitors have the benefit of delivering immediate results and do not need extensive training, making them applicable to primary care, pulmonology, and pediatric departments.
This technology can support diagnosis and personalize treatment, positively reducing unnecessary prescribing of corticosteroids in hospitals and clinics and improving patient outcomes. Due to this, nitric oxide asthma testing landscape is once again dominated by both handheld monitors and institutional end users.
| Product Type | Market Share (2025) |
|---|---|
| Nitric Oxide Testing Handheld Monitor | 54.2% |
On the basis of product type, the handheld nitric oxide testing monitors segment holds the leading market share, owing to their capability to deliver accurate results through a simple breath analysis within a few minutes. Portable, battery-operated kits, such as these novel devices, can be easily transported and run in outpatient clinics, general practice offices and home environments.
Braeuninger et al present an interesting analysis using data from the Asthma Research Network showing that healthcare providers who measure fractional exhaled nitric oxide (FeNO) using handheld monitors an established biomarker of eosinophilic airway inflammation that correlates well with asthma severity and treatment response can use these data to guide care and improve outcomes for patients with asthma.
Clinicians are biased toward handheld monitors because they can assist real-time decision-making at the time of a patient visit. These devices are portable, allowing for asthma testing in multiple care settings without laboratory infrastructure or specialist equipment.
Manufacturers have improved their usability with intuitive interfaces, Bluetooth connectivity, and integration with electronic health records (EHRs). As healthcare systems continue to stress the importance of early detection and management of disease, handheld monitors remain a low-cost, scalable solution that assists in avoiding hospitalizations and improving long-lasting care of asthma.
| End-user Segment | Market Share (2025) |
|---|---|
| Hospitals and Clinics | 61.8% |
Because of their primary role in the diagnosis and management of asthma across patient populations, hospitals and clinics represent the largest end users in the nitric oxide asthma testing market. Such environments provide the infrastructure and clinical expertise to integrate FeNO testing into routine respiratory assessments.
In emergency rooms, pediatric asthma clinics, and pulmonology departments, nitric oxide testing improves the ability to confirm diagnosis, evaluate levels of inflammation, and track patient response to inhaled corticosteroids or other controller therapies.
Routine testing for nitric oxide would allow hospitals to eliminate some of the variability in asthma treatment, reduce over-prescription of some medications, and identify patients on co-morbid medications within the asthma therapeutic environment. Clinics also employ these systems for tracking inflammation over time as well, supporting personalized care and improved long-term control of asthma symptoms.
More so, they expand on existing reimbursement pathways and existing clinical guidelines that encourage the use of FeNO testing for institutional end users. While nitric oxide testing solutions can certainly contribute to previously mentioned pay for performance models by facilitating the spread of more targeted diagnosis and treatment, hospitals and clinics will continue to play a key role in enabling this adoption more broadly.
The nitric oxide asthma testing market is a fairly specialized and consolidated segment of the respiratory diagnostics market. These tests help clinicians monitor eosinophilic airway inflammation, guide inhaled corticosteroid therapy and minimize exacerbation risk by measuring fractional exhaled nitric oxide (FeNO).
Portable FeNO analyzers with digital readout integration, pediatric usability, and clinical validation are key trends among players. The market encompasses respiratory device manufacturers, diagnostic companies, and pulmonary care innovators, serving customers in hospitals, clinics, and primary care environments.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Circassia Group plc (NIOX Group) | 30-35% |
| Bedfont Scientific Ltd. | 20-24% |
| Cohero Health (Aptar Group) | 10-14% |
| Siemens Healthineers AG | 8-12% |
| Intersurgical Ltd. | 5-9% |
| Other Companies (combined) | 15-20% |
| Company Name | Key Offerings/Activities |
|---|---|
| Circassia Group plc | Released NIOX VERO® next-gen FeNO monitor in 2024, designed for point-of-care testing with Bluetooth data sync and asthma control tracking. |
| Bedfont Scientific Ltd. | Launched NObreath® FeNO analyzer update in 2025, offering cost-effective exhaled NO measurements with pediatric flow rates. |
| Cohero Health | Integrated FeNO sensors into mobile-connected asthma management systems in 2024, supporting remote diagnostics and medication adherence. |
| Siemens Healthineers AG | Introduced FeNO module as part of broader pulmonary function testing systems in 2025, enhancing hospital-based diagnostics. |
| Intersurgical Ltd. | Developed disposable mouthpieces and FeNO-compatible consumables in 2024, improving hygiene and workflow in clinical testing. |
Key Company Insights
Circassia Group plc
Circassia dominates the FeNO segment with NIOX VERO®, used widely in clinical and primary care settings for its ease of use, validated accuracy, and mobile app compatibility.
Bedfont Scientific Ltd.
Bedfont offers affordable FeNO testing devices, supporting both adult and pediatric patients with compact systems suitable for outpatient asthma programs.
Cohero Health
Cohero Health, part of Aptar Group, leads in connected respiratory care, integrating FeNO monitoring with mobile apps and smart inhaler platforms for full asthma control.
Siemens Healthineers AG
Siemens adds value by embedding FeNO within multifunctional lung testing suites, enabling holistic respiratory diagnostics in hospital and lab settings.
Intersurgical Ltd.
Intersurgical enhances FeNO adoption with disposable accessories, focusing on infection prevention, cost efficiency, and system compatibility.
Other Key Players (15-20% Combined)
Several other companies contribute to the nitric oxide asthma testing market, focusing on wearable sensors, telehealth integration, and point-of-care innovation:
The overall market size for the nitric oxide asthma testing market was USD 2,751.4 million in 2025.
The nitric oxide asthma testing market is expected to reach USD 4,439.3 million in 2035.
The increasing prevalence of asthma and respiratory disorders, rising demand for non-invasive diagnostic tools, and growing adoption of handheld monitors and hospital-based testing fuel the nitric oxide asthma testing market during the forecast period.
The top 5 countries driving the development of the nitric oxide asthma testing market are the USA, UK, European Union, Japan, and South Korea.
Handheld monitors and hospital-based testing lead market growth to command a significant share over the assessment period.
Protein Diagnostics Market Share, Size and Forecast 2025 to 2035
CGRP Inhibitors Market Trends - Growth, Demand & Forecast 2025 to 2035
Indolent Systemic Mastocytosis treatment Market Insights: Size, Trends & Forecast 2025 to 2035
Lung Cancer PCR Panel Market Trends, Growth, Demand & Forecast 2025 to 2035
Polymyxin Resistance Testing Market Trends – Innovations & Growth 2025 to 2035
Procalcitonin (PCT) Assay Market Analysis by Component, Type, and Region - Forecast for 2025 to 2035
Nitric Oxide Asthma Testing Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
